NG-350A plus chemoradiotherapy for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a new virus-based therapy (NG-350A) combined with standard chemoradiotherapy for people with locally advanced rectal cancer. It aims to see if the combination is safe and can help shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed type of rectal cancer called adenocarcinoma that is locally advanced (stage II or III).
- Your tumor must be microsatellite stable (MSS) or proficient mismatch repair (pMMR) – a test your doctor can do.
- You should be in good enough health to carry out daily activities (ECOG score 0 or 1).
- You cannot be pregnant or breastfeeding, and if sexually active you must agree to use contraception.
- You must not have had prior surgery or radiation for rectal cancer, or certain other medical conditions as listed in the full criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of focused radiation therapy given quickly, along with chemotherapy, targeted drugs, and immunotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve survival chances by treating the cancer aggressively before an operation.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (PD-1 inhibitor) before surgery for locally advanced rectal cancer located below the peritoneal reflex. The goal is to see if this approach improves outcomes.
This trial tests a combination of brief radiation therapy, two chemotherapy drugs (nal-IRI and capecitabine), and an immunotherapy drug (camrelizumab) for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes before surgery.
This trial tests a combination of short-course radiation, two chemotherapy drugs (liposomal irinotecan and capecitabine), and an immunotherapy drug (Enlonstobart) for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor before surgery.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.